16.3 billion anti-allergic drug market business opportunities are "sensitive"

Nowadays, it is a good time for spring to return to the earth and all things to recover, but many people suffer from "allergies"
.
Allergic diseases refer to tissue damage or physiological dysfunction caused by the stimulation of the body by antigenic substances (allergens), which are abnormal or pathological immune responses
.
The most common allergens are mites and molds in dust, clothes, toys, and animals; the second is pollen, so spring and autumn are the seasons for allergic diseases
.
Common ones include allergic rhinitis, allergic asthma, skin allergies (eczema, urticaria) and allergic dermatitis
.
Allergic reactions are also called "allergies".
The PDB database classifies anti-allergic drugs as a treatment category called "anti-allergic drugs", while allergic asthma drugs are classified under the "anti-asthmatic" treatment sub-category of respiratory medicines In this article, the market analysis of "antiallergic drugs" and "asthma drugs" is carried out
.
According to the PDB database, the total sales of antiallergic drugs and antiasthmatic drugs in public hospitals nationwide in 2021 will be about 16.
3 billion yuan
.
Anti-allergic drugs, local companies control 80% of sales According to the data, the sales of anti-allergic drugs in sample hospitals in 2021 will be 1.
303 billion yuan, and the purchase amount of drugs in public hospitals across the country will be about 3.
714 billion yuan
.
During the five years from 2017 to 2021, the sales in the first three years have been rising steadily.
In 2019, the sales of the sample hospitals were 1.
407 billion yuan, the highest value in the five years
.
Due to the sudden impact of the new crown epidemic, there was a large decline in 2020
.
With the normalized management of the epidemic, sales will recover in 2021
.
The top three products occupy half of the country.
From the quarterly perspective of each year, the sales of antiallergic drugs have a certain seasonality, which also shows that in spring and autumn, due to the blooming of flowers and the increase in the number of pollen, the number of allergic people and medical treatment has increased.

.
From the perspective of drugs, there will be 34 anti-allergic drugs sold in the sample hospitals in 2021, and the top three sales of desloratadine, dust mites, and ebastine will account for 50.
49%, accounting for half of the total sales.
above
.
Yangzijiang Pharmaceutical ranks first.
From the perspective of enterprises, there will be 181 manufacturers selling antiallergic drugs in the sample hospitals in 2021, of which the sales of Yangzijiang Pharmaceutical Group (including 4 subsidiaries) will account for 29.
67%, ranking first
.
The sales of the TOP15 sample hospitals of the manufacturers accounted for 74.
75% of the total sales, about three-quarters
.
Among the 181 companies, 168 are local pharmaceutical companies and 13 are foreign-funded pharmaceutical companies
.
Sales of local pharmaceutical companies accounted for 83.
27%, and foreign pharmaceutical companies accounted for 16.
73%
.
Anti-asthmatic drugs are prominent in the head pattern of foreign-funded enterprises.
Data show that in 2021, the sales of anti-asthmatic drugs in sample hospitals will be 3.
42 billion yuan, and the purchase amount of drugs in public hospitals across the country will be about 12.
551 billion yuan
.
From 2017 to 2021, the sales of the sample hospitals in 2019 were the highest, reaching 4.
297 billion yuan
.
In 2020, there will be a larger decline, which is also due to the sudden impact of the new crown epidemic.
In 2021, sales will recover after the normalized management of the epidemic
.
TOP10 drugs account for 90% of the share.
From the perspective of drugs, 32 anti-asthmatic drugs will be sold in sample hospitals in 2021, including budesonide, budesonide + formoterol compound, terbutaline, montelukast and fluticasone + Salmeterol compound is in the top four
.
The total sales of TOP10 drug sample hospitals exceeded 2.
996 billion yuan, accounting for 87.
60%, indicating a high degree of concentration
.
Local companies still need to catch up.
From the perspective of companies, there will be 151 manufacturers selling anti-asthmatic drugs in sample hospitals in 2021, of which the sales of AstraZeneca’s two companies account for 41.
53%, ranking first, indicating that the top Enterprise phenomenon is very obvious
.
The sales of the top 15 manufacturers accounted for 81.
0% of the total sales, more than four-fifths
.
Among the 151 companies, 137 are local pharmaceutical companies and 14 are foreign-funded pharmaceutical companies
.
Foreign pharmaceutical companies accounted for 62.
44% of the sales of anti-asthma drugs in the sample hospitals; local pharmaceutical companies accounted for 37.
56%, indicating that local pharmaceutical companies still have a lot of room for development
.
Summary According to the statistics of WHO, in the process of industrialization, the proportion of people with seasonal allergies in the world has continued to rise in the past 50 years, and the proportion of children allergic to one or more allergens has reached as high as 50%
.
In the future, more and more anti-allergic drugs will be used to treat allergies
.
In China, on the one hand, with the implementation of the previous batches of national centralized procurement, antiallergic drugs such as levocetirizine, desloratadine, cetirizine, loratadine, bepotastine, etc.
Drugs such as montelukast, albuterol, doxofylline, etc.
have also entered the centralized procurement, which has the effect of reducing the sales amount but increasing the amount of use, covering more patient groups and reducing the burden on patients and medical insurance; on the other hand , with the launch of more new drugs, such as anti-allergic drug Artemisia annua pollen allergen sublingual drops and targeted biological agents omalizumab, dupilimumab, etc.
have been launched and entered the country one after another, especially monoclonal antibodies The relatively high price will inevitably increase the sales amount in this field.
At the same time, it will be used as a new treatment method to meet clinical needs and provide more treatment options for different patients
.